02Aug
FDA Issues Cannabidiol Marketing Warning as Congressional Pressure for Action Continues
Following through with its promise to take enforcement actions against companies marketing cannabis-derived products that could put consumers at risk, the Food and Drug Administration (FDA) recently issued a warning letter to Curaleaf Inc., a...
By:
Wilson Sonsini Goodrich & Rosati
Related
"The ins and outs of I-9 Compliance," HR Dive - The I-9 process can cause confusion for many employ...
Read More >
New York State has banned discrimination against hairstyles or textures associated with race....By: ...
Read More >
In a market with soaring multiples, private equity buyers are increasingly on the hunt to mitigate h...
Read More >
Please join us for a webinar covering the latest updates to Washington’s Paid Family and Medical Le...
Read More >
On January 16, 2020, the Department of Labor (DOL) published a final rule that brings much-needed cl...
Read More >
ERISA requires disclosure of certain plan documents to participants including a summary plan descrip...
Read More >